Overall rank by patents
#3,002
of 50,000 tracked assignees
USPTO PatentsView assignee record - 127 granted patents across 21 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
According to USPTO PatentsView, Whitehead ranks #3,002 of 50,000 tracked US assignees by granted-patent volume, with 127 patents across 21 technology areas.
Whitehead Institute For Biomedical Research has been granted 127 US utility patents between 2015 and 2025, placing Whitehead Institute For Biomedical Research at #3,002 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 21 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.8 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Whitehead Institute For Biomedical Research is one of the more focused assignees in the PatentsView dataset. By volume, Whitehead sits between Universite Pierre Et Marie Curie (paris 6) (127 patents, rank #2,998) and Ceres, Inc. (126 patents, rank #3,006) - the closest US assignees by grant volume. The composite Innovation Score of 54.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 49 grants, compared with 68 in the 2015–2019 window, a -28% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Whitehead Institute For Biomedical Research's 18.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 21 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Universite Pierre Et Marie Curie (Paris 6)
127 patents
VODAFONE IP LICENSING LIMITED
127 patents
W. KORDES' SÖHNE Rosenschulen GmbH & Co KG
127 patents
WANGSU SCIENCE AND TECHNOLOGY CO., LTD.
127 patents
Wyeth, LLC
127 patents
Whitehead Institute For Biomedical Research
127 patents
Abb Vie Deutschland Gmbh & Co. KG
126 patents
CHATSWORTH PRODUCTS, INC.
126 patents
Ceres, Inc.
126 patents
What this shows Whitehead holds 127 patents at rank #3,002, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #3,002 in granted patent volume.
Other assignees with the most granted patents in Whitehead's primary technology class.
Two PlainPatent-derived peer sets for Whitehead, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (54 here).
Nearest assignees by average claims per patent (18.8 here).
Whitehead's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 19 | 15.0% |
| 2016 | 9 | 7.1% |
| 2017 | 18 | 14.2% |
| 2018 | 13 | 10.2% |
| 2019 | 9 | 7.1% |
| 2020 | 5 | 3.9% |
| 2021 | 9 | 7.1% |
| 2022 | 16 | 12.6% |
| 2023 | 9 | 7.1% |
| 2024 | 10 | 7.9% |
| 2025partial year | 10 | 7.9% |
Top 15 of 21 technology areas
Historical grant data only; it does not rate legal strength or current strategy.
Overall rank by patents
#3,002
of 50,000 tracked assignees
54.4 out of 100
How to use this portfolio
Whitehead's 127 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.